Navigation Links
EnWave Announces Collaboration and Initial Testing Results with Danisco AS

VANCOUVER, April 7 /PRNewswire-FirstCall/ - EnWave Corporation (TSX-V: ENW) ("EnWave" or "the Company") today announced the successful completion of tests using its recently developed powderREV technology in the dehydration of cultures and probiotics from the Danish group Danisco. The tests were conducted as the first phase of an Agreement signed with Danisco last year. The objective of the agreement is to create a dehydration method delivering high-speed continuous bulk powder processing capable of handling sensitive biological materials, such as cultures.

powderREV is a new Radiant Energy Vacuum (REV) process designed to convert a liquid stream of biological materials into bulk powder on a continuous basis. Preliminary tests on cultures were conducted at EnWave's Vancouver lab using the single-vial REV prototype. Post-dehydration bioactivity levels from the REV dehydration methods show that REV-dried cultures are capable of achieving equivalent, or possibly better bioactivity for certain cultures than freeze-dried samples.

Based on the success of these early results, EnWave and Danisco will now undertake the second phase of the Agreement to evaluate the commercial viability of EnWave's powderREV dehydration technology on a wider scope. The terms of the Agreement grant Danisco with exclusivity for a limited period of time. EnWave and Danisco expect this second phase to be completed in the 2nd quarter of 2010.

"We are excited by the opportunity to test our new powderREV technology with a leading global player in the food culture industry," said Dr. Tim Durance chairman and Co-CEO of EnWave. "We intend to build on the success of the phase one tests and look forward to exploring future collaboration opportunities with Danisco".

With 7,200 employees operating from more than 80 locations in the world, Danisco reported annual revenues of 18.7 billion DKK (US$3.1 billion) in its 2007/2008 year end results. The Danish group is a global leading supplier of cultures and probiotics for food, supplements and feed and holds a dominant position in cultures under dried form. Easier to handle, dried cultures bring greater flexibility to manufacturers in terms of storage volume and conditions as well as shelf-life stability.

"Danisco has always been proactive in searching for innovative technologies to improve the drying process of cultures," said Egon Bech Hansen, Danisco's Cultures Division Vice President R&D. "The initial results from the tests with EnWave's technology are encouraging. We are looking forward to expanding the testing on a larger scale prototype to better evaluate potential product and economic advantages".

If powderREV technology can demonstrate commercial feasibility on a scale, schedule and terms acceptable to both parties, EnWave would plan to enter a commercial sales and exclusive license agreement with Danisco.

About Danisco

With a rich and innovative portfolio, Danisco is a world leader in food ingredients, enzymes and bio-based solutions. Using nature's own materials, science and the knowledge of our 7,200 people, Danisco designs and delivers bio-based ingredients that meet market demand for healthier and safer products. Danisco's ingredients are used globally in a wide range of industries - from bakery, dairy and beverages to animal feed, laundry detergents and bioethanol - offering functional, economic and environmental benefits. Headquartered in Denmark and operating from more than 80 locations, Danisco's key focus is to become customers' first choice and a truly market-driven global business. Find out more at

About EnWave

Using proprietary technologies developed in conjunction with the University of British Columbia, EnWave is focused on the development of new methods of dehydrating biological and food materials using Radiant Energy Vacuum technology under its bioREVTM, freezeREV, nutraREVTM and powderREV brands. REV technology combines microwave energy transfer with pressure control to dehydrate and alter structures and drive chemical reactions, thereby creating unique product characteristics for both food products and medical applications that include dry vaccines and antibodies. More information about EnWave is available at

    EnWave Corporation
    Mr. John McNicol
    President & Co-CEO

This press release may contain forward-looking information based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. The forward-looking statements in this press release include: "EnWave intends to" and "EnWave expects". These statements are not a guarantee of future performance and involve a number of risks, uncertainties and assumptions: there is no guarantee that the Company's powderREV technology can or will improve processes in the food culture industry; even if the Company's powderREV technology can be used as described in this document, there is no guarantee that such use will result in orders for the Company's powderREV technology.

    The TSX Venture Exchange has neither approved nor disapproved the
    information contained herein.

    Neither the TSX Venture Exchange nor its Regulation Services Provider (as
    that term is defined in the policies of the TSX Venture Exchange) accepts
    responsibility for the adequacy or accuracy of this release.

SOURCE EnWave Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology
2. Microbix Announces A New Technology Platform For The SST Project
3. Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial
4. Caliper Life Sciences Announces Date and Location of its 2009 Annual Meeting of Stockholders
5. Immunotech Laboratories Announces South American Strategy
6. Siemens Healthcare Announces Planned Collaboration with Harris Corporation
7. ChromaDex Announces 2008 Year End Financial Results
8. China Agri-Business Announces 2008 Operating Results
9. Verenium Announces Organizational Changes
10. ThermoGenesis Announces Abstracts to Be Presented at Upcoming Stem Cell Therapy Conference
11. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis
Post Your Comments:
(Date:11/30/2015)... San Jose, CA (PRWEB) , ... ... ... the Content Intelligence Company, today announced tighter software integration with MarkLogic, the ... management where organizations maximize information to drive change. , Smartlogic’s Content Intelligence ...
(Date:11/27/2015)... 27, 2015 ... of companion diagnostics is one of the ... with pharmaceutical companies and diagnostic manufacturers working ... . --> ... on global cancer biomarkers market spread across ...
(Date:11/25/2015)... 25, 2015 2 nouvelles études permettent ... les différences entre les souches bactériennes retrouvées dans la ... des êtres humains . Ces recherches  ouvrent une nouvelle ... prise en charge efficace de l,un des problèmes ... chats .    --> 2 nouvelles études ...
(Date:11/25/2015)... ... November 25, 2015 , ... A long-standing partnership between ... (OPBAP) has been formalized with the signing of a Memorandum of Understanding. , ... leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at ...
Breaking Biology Technology:
(Date:11/17/2015)... -- Paris , qui s,est ... Paris , qui s,est tenu du 17 ... de l,innovation biométrique, a inventé le premier scanner couplé, ... la même surface de balayage. Jusqu,ici, deux scanners étaient ... empreintes digitales. Désormais, un seul scanner est en mesure ...
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
Breaking Biology News(10 mins):